Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections

Table 2 Comparison of the area of hard exudates, the proportion of remaining hard exudates, vision, and central macular thickness in each drug group (triamcinolone, dexamethasone implant, and bevacizumab group) before and after injection. The measurements at each month after injection were compared to pre-injection

		Pre-injection (1)	Month 1 (2)	Month 2 (3)	Month 3 (4)	P-value*	Post-Hoc^†
		Pre-injection (1)	Month 1 (2)	Month 2 (3)	Month 3 (4)	P-value*	1 vs 2	1 vs 3	1 vs 4
HEs area, pixel ratio	Triamcinolone	0.52 ± 0.27	0.28 ± 0.15	0.28 ± 0.14	0.28 ± 0.14	<0.001	<0.001	<0.001	<0.001
	Dexamethasone implant	0.70 ± 0.27	0.52 ± 0.50	0.45 ± 0.25	0.39 ± 0.15	0.053
	Bevacizumab	0.55 ± 0.41	0.51 ± 0.42	0.49 ± 0.33	0.47 ± 0.43	0.150
Proportion of remaining HEs area, %	Triamcinolone	100	53.5 ± 4.91	53.0 ± 4.66	52.9 ± 4.21	<0.001	<0.001	<0.001	<0.001
	Dexamethasone implant	100	79.8 ± 4.10	70.1 ± 5.21	63.6 ± 6.08	<0.001	0.061	<0.001	<0.001
	Bevacizumab	100	92.4 ± 3.31	89.0 ± 4.12	85.2 ± 5.07	0.055
IOP, mmHg	Triamcinolone	16.7 ± 2.72	19.5 ± 3.19	20.7 ± 3.31	19.2 ± 2.96	<0.001	<0.001	<0.001	0.002
	Dexamethasone implant	16.3 ± 2.77	16.4 ± 4.21	16.3 ± 2.56	16.4 ± 2.71	0.984
	Bevacizumab	16.9 ± 2.41	17.1 ± 2.18	16.5 ± 3.77	17.3 ± 2.91	0.322
BCVA, log MAR	Triamcinolone	0.64 ± 0.18	0.42 ± 0.40	0.44 ± 0.31	0.56 ± 0.39	<0.001	<0.001	0.001	0.221
	Dexamethasone implant	0.78 ± 0.10	0.51 ± 0.35	0.53 ± 0.42	0.56 ± 0.40	0.004	0.001	0.001	0.007
	Bevacizumab	0.63 ± 0.12	0.39 ± 0.24	0.44 ± 0.27	0.40 ± 0.25	<0.001	<0.001	<0.001	<0.001
CMT, μm	Triamcinolone	399.2 ± 192.3	250.1 ± 70.3	215.2 ± 43.7	235.5 ± 50.8	<0.001	<0.001	<0.001	<0.001
	Dexamethasone implant	510.3 ± 200.1	262.8 ± 110.8	226.7 ± 101.5	218.4 ± 110.4	<0.001	0.001	<0.001	<0.001
	Bevacizumab	451.3 ± 220.2	315.9 ± 151.2	301.3 ± 153.8	312.8 ± 172.5	<0.001	<0.001	<0.001	<0.001

*Repeated measures ANOVA (analysis of variance) test; ^†Post-hoc Bonferroni test
HEs Hard exudates, BCVA Best corrected visual acuity, IOP Intraocular pressure, BCVA Best corrected visual acuity, CMT Central macular thickness
Values are presented as mean ± standard deviation (SD)

ISSN: 1471-2415